Lung Cancer in Vietnam

Trần, Hương Thanh; Nguyen, Sang M.; Nguyen, Kiem K.; Pham, Dung X.; Nguyen, Uoc Huu; Le, Anh‐Tuan; Nguyen, Giang Huong; Tran, Danh Van; Phung, S.; Do, Hung M.; Tran, Tien Anh; Shu, Xiao‐Ou; Osarogiagbon, Raymond U.

doi:10.1016/j.jtho.2021.06.002

Cited by 12 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, there are five comprehensive cancer centers and 70 oncology departments located within center/tertiary and provincial hospitals throughout Vietnam. 26 The Vietnam National Cancer Hospital and Hanoi Oncology Hospital are two of five comprehensive cancer centers. Cancer patients in Vietnam often seek medical care at center/tertiary hospitals after the recognition of first symptoms or are referred to cancer centers or tertiary hospitals for diagnosis confirmation.…”

Section: Discussionmentioning

confidence: 99%

Delay in the diagnosis and treatment of breast cancer in Vietnam

Nguyen

Nguyen³

et al. 2021

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Delay in the diagnosis and treatment of breast cancer in Vietnam

Nguyen

Nguyen³

et al. 2021

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Western countries, most EGFR-mutant patients are nowadays treated with Osimertinib as a first-line EGFR TKI treatment. However, as the less expensive first- and second-generation TKIs are still in use in many (developing) countries, this study remains relevant [ 37 , 38 , 39 , 40 ]. Moreover, our finding that a pre-existing T790M resistant mutation is very rare may be generalized to other TKI-related resistance mutations.…”

Section: Discussionmentioning

confidence: 99%

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare

Kok

Tan

et al. 2022

Cancers

View full text Add to dashboard Cite

EGFR-mutated non-small cell lung cancer (NSCLC) patients can be effectively treated with tyrosine kinase inhibitors (TKI) but frequently present with an EGFR T790M resistance mutation at relapse. We aimed to screen for T790M in pre-treatment formalin-fixed and paraffin-embedded (FFPE) tissue samples of patients with a confirmed T790M mutation at progression. We analyzed 33 pre-treatment DNA samples of NSCLC patients who progressed upon TKI between 2013 to 2019. To establish storage-time dependent formalin fixation-induced background levels for C>T mutations, we analyzed DNA isolated from archival (stored >1 year, n = 22) and recently generated (stored <1 month, n = 11) FFPE samples and included DNA isolated from white blood cells (WBC) (n = 24) as controls. DNA samples were analyzed by droplet digital (dd)PCR, and positivity was defined by outlier detection according to Grubb’s criterion. The T790M background allele frequency levels were 0.160% in DNA isolated from archival-FFPE, 0.100% in fresh FFPE, and 0.035% in WBC. Progression-free survival (PFS) time of the single T790M positive patient was 9 months, while T790M negative patients had a median PFS of 10 months (range 2–27). Proper storage time matched FFPE control samples are essential for reliable detection of T790M mutation at low VAF. The presence of EGFR T790M mutations in pre-TKI samples is rare, even in patients who progressed with EGFR T790M mutations.

show abstract

“…21 VATS is being increasingly used in countries like Brazil and Vietnam. 22,23 RATS is less commonly available in most of these countries except for China, where robotic technology is rapidly advancing. 24,25 In countries with a high incidence of pulmonary infections, like India and Nepal, there is a concern for increased lung fibrosis and pleural adhesions making minimally invasive surgical resection less feasible.…”

Section: Management Of Non-metastatic Lung Cancermentioning

confidence: 99%

“…28 Hence, their use is limited as a second-line treatment for affluent patient populations in the tertiary healthcare systems. 23,35 Immunotherapy (IO): In the non-oncogene-addicted metastatic NSCLCs, an addition of immunotherapy significantly improved response rates and survival outcomes when compared with standard chemotherapy. [36][37][38][39] Similarly, in small cell lung cancer (SCLC), an addition of immunotherapy to chemotherapy improved OS and PFS irrespective of PDL1 immunohistochemistry.…”

Section: Management Of Metastatic Lung Cancermentioning

confidence: 99%

Lung cancer management in low and middle-income countries - current challenges and potential solutions

Uprety

Surapaneni

2023

International Journal of Cancer Care and Delivery

View full text Add to dashboard Cite

Lung cancer is the second-most prevalent cancer and, the most common cause of cancer-related mortality throughout the world. Evidence-based strategies to decrease its incidence and mortality are being implemented in different parts of the world. Smoking cessation policies are being actively publicized to decrease the incidence of tobacco related cancers including lung cancer. Screening program for early detection of localized lung cancer which can then be targeted by a multimodality approach utilizing surgery, radiation, chemoimmunotherapy to achieve cure is now becoming the standard in several high-income countries. Precision medicine in lung cancer is booming with metastatic non-curative cancers targeted with small molecule tyrosine kinase inhibitors. However, these advancements are not available all around the world. Inequalities exist in the management of lung cancer, mostly driven by the economic differences between the countries. Raising awareness to these international barriers is pivotal for improving lung cancer related incidence and mortality.

show abstract

Lung Cancer in Vietnam

Abstract: having stock ownership in Eli Lilly, Gilead Sciences, and Pfizer; being the founder of Oncobox Device, Inc.; and having issued patents for a lymph node specimen collection kit. The remaining authors declare no conflict of interest.

Cited by 12 publications

References 7 publications

Delay in the diagnosis and treatment of breast cancer in Vietnam

Delay in the diagnosis and treatment of breast cancer in Vietnam

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare

Lung cancer management in low and middle-income countries - current challenges and potential solutions

Contact Info

Product

Resources

About